SynthesisThe Cochrane database of systematic reviews2000
Haemodilution for acute ischaemic stroke.
Synthesis in The Cochrane database of systematic reviews, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 76 citations in OpenAlex.
- Serum Osmolality and Stroke Mortality in the ICU: A U-Shaped Risk Pattern and Its Clinical Implications.Journal of clinical medicine · 2025Article
- Management of cerebral vasospasm.Neurosurgical review · 2006Review
Corrections and comments
- Updated by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIschaemic stroke interrupts the flow of blood to part of the brain. Haemodilution is thought to improve the flow of blood to the affected areas of the brain.
objectivesThe objective of this review was to assess the effects of haemodilution in acute ischaemic stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group trials register, Medline and conference abstracts. We contacted manufactures and investigators in the field. SELECTION CRITERIA: Randomised trials of haemodilution treatment in people with acute ischaemic stroke. Only trials where treatment was started within 72 hours of stroke onset were included. DATA COLLECTION AND ANALYSIS: Two reviewers assessed trial quality and independently extracted the data. MAIN
resultsSixteen trials were included. A combination of venesection and plasma volume expander was used in eight trials. Eight trials used plasma volume expander alone. The plasma volume expander was dextran 40 in 11 trials, hydroxyethyl starch in four trials and albumin in one trial. Two trials tested haemodilution in combination with another therapy. Evaluation was blinded in 11 trials. Five trials probably included some patients with intracerebral haemorrhage. Haemodilution did not significantly reduce deaths within seven to 28 days (odds ratio 1.12, 95% confidence interval 0.88 to 1.43). Similarly, haemodilution did not influence deaths within three to six months (odds ratio 1.02, 95% confidence interval 0.85 to 1.23), or death and dependency or institutionalisation (odds ratio 1.01, 95% confidence interval 0.86 to 1.19). The results were similar in confounded and unconfounded trials, in trials of isovolaemic and hypervolaemic haemodilution, and in trials using different types of hemodiluting agents. Six trials reported venous thromboembolic events. There was a tendency towards reduction in deep venous thrombosis and/or pulmonary embolism at three to six months follow-up (odds ratio 0.59, 95% confidence interval 0.33 to 1.06). REVIEWER'S
conclusionsThe overall results of this review are compatible both with a modest benefit and a moderate harm of haemodilution therapy for acute ischaemic stroke. As used in the randomised trials, this therapy has not been proven to improve survival or functional outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.